Wechselwirkungen · Akynzeo
Akynzeo 235 mg/0.25 mg concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 40
HOS-130785 · Präparat HOS-096947
Administration of the CYP3A4 inhibitor ketoconazole with netupitant/palonosetron capsules administered orally increased the AUC of netupitant 1.8 fold and Cmax 1.3 fold when compared to the administration of Akynzeo alone. Co-administration with ketoconazole did not affect the pharmacokinetics of palonosetron. Administration of the CYP3A4 inducer rifampicin with Akynzeo administered orally alone decreased the AUC of netupitant 5.2 fold and Cmax 2.6 fold. Co-administration of rifampicin did not affect the pharmacokinetics of palonosetron. Consequently, concomitant administration with strong CYP3A4 inhibitors (e.g., ketoconazole) should be approached with caution and concomitant administration with strong CYP3A4 inducers (e.g. rifampicin) should be avoided.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ketoconazole (HOS-084513)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-25T11:52:00Z · SHA-256 d3ff78e9e4d5b08bc98e527fab724082b02f5be1899a4d4f9c683d723854e46c · Passage b0303d6ddbaa9c18dcc046af4483c8c5598fb3f5979d204691f9a5616c42cade · Zeichen 4630–5395 im Abschnitt